ABX Abacus Life, Inc. Insider Trading

CFO buys 33,000 shares of ABL at $5.82; 2 other insiders also bought in past 14 days; stock down 48.4% from 52-week high.

William Hugh McCauley Jr., CFO of Abacus Global Management, purchased 33,000 shares at $5.82 on 2025-06-04, increasing his holdings to 87,000 shares (+61.1% net change). This transaction is part of a cluster pattern: 2 other insiders also bought within the past 14 days, suggesting coordinated insider accumulation at depressed valuations. The stock is trading at $6.05, down 48.4% from its 52-week high of $11.73 and down 26.7% over the past 30 days, while the company reported strong revenue growth of 68.6% year-over-year and a profitable latest quarter ($4.6M net income). However, the company was unprofitable over its most recent full fiscal year, signaling structural profitability challenges despite near-term improvements. The cluster buy pattern combined with significant recent price weakness presents a data point for investor attention: insiders are accumulating while the stock faces severe drawdown, but the underlying full-year losses warrant caution on the sustainability of recent quarterly gains.

Co-Founder McNealy buys 86,207 shares at $5.77; stock down 48.4% from $11.73 high, yet cluster pattern emerges with 2 other insiders buying in past 14 days

Sean McNealy, Co-Founder and President, purchased 86,207 shares at $5.77 on 2025-06-04, bringing his holdings to 12,455,707 shares. The purchase occurs after a severe drawdown: ABL has fallen 48.4% from its 52-week high of $11.73 and is down 26.7% over the past 30 days. McNealy's same-ticker history at ABL shows a 3-of-3 well-timed pattern—his prior two sales in late 2024 each preceded further declines, and his prior buy in November 2023 captured a +99.4% 90-day gain. However, the company posted negative full-year net income despite strong revenue growth of 68.6% year-over-year and current quarterly profitability of $4.6M on $44.1M revenue. The meaningful signal here is not isolated conviction but the cluster: 2 additional insiders also purchased within the past 14 days, suggesting coordinated or near-simultaneous leadership confidence at depressed levels. This cluster activity, combined with McNealy's demonstrated timing acuity at this ticker and the sharp price decline, warrants investor attention to whether management believes the drawdown is reversible.

Co-Founder Scott buys 86,207 ABL shares at $5.77; stock -48.4% from 52-week high, company unprofitable in last fiscal year despite 68.6% revenue growth

Kevin Scott, Co-Founder and President, purchased 86,207 shares at $5.77 on 2025-06-04, bringing total holdings to 12,447,415 shares. The purchase occurs as ABL trades -48.4% from its 52-week high of $11.73 and has declined -26.7% over the preceding 30 days. While the company reports strong revenue growth of 68.6% year-over-year with latest quarterly revenue of $44,139,346.00, it was unprofitable over its most recent full fiscal year, creating ambiguity about near-term earnings sustainability. A cluster of 2 additional insider purchases within 14 days of this transaction suggests coordinated confidence among management, though Scott's own cross-ticker track record of 100% well-timed sell timing at the 90-day mark indicates his historical trades have been opportunistic rather than conviction-driven.

CEO Jackson Jay J sold 75,800 shares of ABL at $8.00 (now $7.80); stock down 26.4% in 90 days amid operating losses.

Jackson Jay J, Chief Executive Officer, sold 75,800 shares at $8.00 on 2024-12-20, reducing his holdings from 9,937,000 shares to 9,861,200 shares. The transaction occurred at a price 2.6% above the current market price of $7.80, though the stock has declined 26.4% over the past 90 days and is 37.4% below its 52-week high of $12.47. The company is currently unprofitable, reporting a net income of $-5,125,055.00 for the latest quarter against revenue of $28,148,491.00, despite strong annual revenue growth of 48.5%. The CEO's prior sell at ABL on 2024-11-21 resulted in a 30-day return of -3.5%, suggesting the recent sale may align with broader downward momentum rather than tactical repositioning ahead of stabilization.

Co-founder Scott sells 75,800 ABL shares at $8.00; stock down 37.4% from 52-wk high despite 48.5% revenue growth

Kirby Kevin Scott sold 75,800 shares at $8.00 on 2024-12-20 while retaining 12.36M shares post-transaction, a 0.6% reduction in his holding. The sale occurs with ABL trading at a 37.4% discount from its 52-week high of $12.47, yet the company posted annual revenue growth of 48.5% in its latest period. The disconnect between strong top-line expansion and depressed valuation—combined with a negative net income of $-5.1M—may explain the equity market discount. His cross-ticker track record shows 1 prior sell with an average 30-day return of -3.5%, and his prior ABL sale on 2024-11-21 also posted a -3.5% 30-day return, indicating a pattern of selling into weakness rather than at peaks.

Co-Founder Matthew Ganovsky sells 75,800 ABL shares at $8.00; stock now $7.80, down 37.4% from 52-week high.

Matthew Ganovsky, Co-Founder and President of Abacus Life, sold 75,800 shares at $8.00 on 2024-12-20, reducing his position from 10.09M to 10.01M shares, a -0.8% reduction in holdings. The transaction occurred 30 days after a prior sell at the same ticker (2024-11-21), continuing a pattern of recent dispositions. The current price of $7.80 reflects a 37.4% decline from the 52-week high of $12.47, though the stock has recovered 3.3% over the past 30 days and sits near its 52-week low. The company reports a net loss of $5.1M on $28.1M in quarterly revenue, with a P/E of 45.88 and revenue growth of 48.5% year-over-year. The timing of consecutive sell transactions during a material drawdown warrants attention to whether they reflect operational cash needs or a reassessment of near-term business prospects.

McNealy sells 75,800 shares of ABL at $8.00 (12-20-2024), maintaining 12.36M shares; stock -37.4% from 52-week high of $12.47

McNealy, Co-Founder and President, sold 75,800 shares at $8.00 for $606,400, reducing holdings by 0.6% to 12.36M shares. The transaction occurs after ABL stock has declined 26.4% over 90 days and 37.4% from its 52-week high of $12.47, though the stock has recovered +3.3% over the past 30 days. His prior sale at this ticker on 2024-11-21 showed a 30-day return of -3.5%, and his historical prior purchase at ABL on 2023-11-16 yielded a 90-day return of +99.4%, demonstrating a mixed pattern at this specific security. The company is growing revenue at +48.5% annually but remains unprofitable, with a net loss of $5,125,055 on revenue of $28,148,491 in the latest quarter, and carries a P/E of 45.88. The modest sale size relative to total holdings and the recent stock recovery provide limited clarity on insider conviction regarding ABL's prospects.

Director Gusky buys 10,000 ABL shares (3 trades, $7.70–$7.85) for $77,600.00; holdings rise 20.4% to 59,085 shares

Adam Samuel Gusky, Director of Abacus Life, Inc., executed 3 separate purchases totaling 10,000 shares for $77,600.00 between December 13 and December 16, 2024, at prices ranging from $7.70 to $7.85 per share. This represents a 20.4% increase in his shareholding from 49,085 to 59,085 shares. His cross-ticker track record shows 19 prior open-market buys with an 83.33% 90-day win rate and average 90-day returns of +19.1%, while his prior trades at ABL specifically—including two buys in November 2023—delivered strong 90-day returns of +104.5% and +99.6%. The current stock price of $7.86 sits 37.0% below the 52-week high of $12.47 and has declined 20.4% over the past 90 days, placing the purchase window at a depressed absolute level within the recent price range. The company is growing revenue at +48.5% year-over-year but remains unprofitable at the latest quarter (-$5.1M net income on $28.1M revenue), suggesting the director's accumulation occurs amid both growth momentum and ongoing operational challenges.

Director Gusky purchases 8,126 shares in 2 tranches at $7.93–$7.94 for $64,474.80; holds 49,085 post-trade after +19.8% increase.

Director Adam Samuel Gusky executed 2 separate purchases totaling 8,126 shares for $64,474.80, increasing his holdings by 19.8% from 40,959 to 49,085 shares. His cross-ticker track record shows 17 prior buys with an 83.33% 90-day win rate and avg 90d return of +19.1%, though his same-ticker history at ABL is more limited: his last two buys (2023-11-16 and 2023-11-17) delivered +99.6% and +104.5% 90-day returns respectively. The current stock price of $8.03 sits 35.6% below the 52-week high of $12.47 and has declined 11.0% over 30 days and 18.4% over 90 days, positioning the purchases near recent lows. Abacus Life reports strong annual revenue growth of 48.5%, though the latest quarter shows a net loss of $5,125,055.00 on revenue of $28,148,491.00, and the P/E of 47.24 reflects a richly-valued profile. The accumulation pattern and scale suggest continued confidence in the equity, though the fundamental losses and valuation metrics present counterbalancing considerations.

Director Gusky bought 18,241 shares of ABL at $7.54 (+80.3% to holdings); prior 2 ABL buys returned +33.7% and +30.6% in 30 days.

Director Adam Samuel Gusky purchased 18,241 shares at $7.54 on 2024-11-22, expanding his stake from 22,718 to 40,959 shares (+80.3%). This mirrors his prior transaction pattern at ABL: his two previous open-market purchases (2023-11-16 and 2023-11-17) each posted positive 90-day returns of +99.6% and +104.5%, indicating a track record of well-timed accumulation at this ticker. His cross-ticker open-market history spans 16 prior buys with an 83.33% 90-day win rate and average 90d return of +19.1%, reinforcing consistent execution discipline. The current environment presents pressure: stock is down 10.2% over 30 days, down 19.2% over 90 days, and trading 35.2% below its 52-week high of $12.47. Despite the depressed price, Gusky's decision to add shares at $7.54 (now trading at $8.08) occurs against a backdrop of profitable revenue growth (+48.5% year-over-year) offset by a $-5.1M net loss in the latest quarter. The timing and magnitude of his purchase—combined with his historical precision at this ticker—warrant close attention to whether this reflects informed confidence in a turnaround or anticipation of near-term catalysts.